(Q37302094)

19 August 2017

1 reference

title

Ranolazine for chronic stable angina (English)

1 reference

19 August 2017

David T Nash

1

1 reference

19 August 2017

Stephen D Nash

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

372

1 reference

19 August 2017

issue

9646

1 reference

19 August 2017

page(s)

1335-1341

1 reference

William Heberden and Some Account of a Disorder of the Breast.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Incidence and prognostic implications of stable angina pectoris among women and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Clinical pharmacokinetics of ranolazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Intracellular Na+ regulation in cardiac myocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Sodium regulation during ischemia versus reperfusion and its role in injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Characteristics of a contemporary population with angina pectoris. TIDES Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Coronary heart disease: the female heart is vulnerable

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Gender differences associated with physical functioning in older persons with angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Gender differences in the management and clinical outcome of stable angina.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Women with coronary artery disease report worse health-related quality of life outcomes compared to men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Exercise treadmill score for predicting prognosis in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Incidence and types of preventable adverse events in elderly patients: population based review of medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Use of preclinical assays to predict risk of drug-induced torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Optimal medical therapy with or without PCI for stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961554-8

7 January 2021

10.1016/S0140-6736(08)61554-8

Identifiers

DOI

1 reference

release_4cmmuzausfgebesjkuo2s5n6ui

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4cmmuzausfgebesjkuo2s5n6ui

24 November 2022

mapped directly with Wikidata item

1 reference